Publications by authors named "Kimberly Gromek"
Article Synopsis
- The study examines the issue of polypharmacy, specifically the harmful prescribing cascade that occurs when anticholinergic medications are used to manage side effects of cholinesterase inhibitors (ChEIs) in patients with severe dementia.
- Researchers conducted a retrospective analysis of Medicare data to identify factors associated with the co-prescribing of these medications and whether stopping ChEIs led to a reduction in anticholinergic use.
- Results indicated that 15% of nursing home residents prescribed ChEIs also received anticholinergics, with certain demographic and clinical factors influencing this co-prescribing, and discontinuing ChEIs often led to a lesser chance of stopping anticholinergic medications.
The last 10-15 years have witnessed a revolution in treating multiple myeloma, an incurable cancer of Ab-producing plasma cells. Advances in myeloma therapy were ushered in by novel agents that remodel the myeloma immune microenvironment. The first generation of novel agents included immunomodulatory drugs (thalidomide analogs) and proteasome inhibitors that target crucial pathways that regulate immunity and inflammation, such as NF-κB.
View Article and Find Full Text PDF